B-intervention	0	6	Inulin
I-intervention	7	22	Supplementation
O	23	30	Reduces
B-condition	31	39	Systolic
I-condition	40	45	Blood
I-condition	46	54	Pressure
O	55	57	in
O	58	63	Women
O	64	68	with
O	69	75	Breast
O	76	82	Cancer
O	83	93	Undergoing
O	94	105	Neoadjuvant
O	106	118	Chemotherapy
O	118	119	.

O	120	126	Breast
O	127	133	cancer
O	134	136	is
O	137	140	the
O	141	145	most
O	146	156	frequently
O	157	166	diagnosed
O	167	177	malignancy
O	178	180	in
O	181	186	women
O	186	187	,
O	188	191	and
O	192	205	comorbidities
O	206	210	like
O	211	223	hypertension
O	224	227	and
O	228	235	obesity
O	236	244	diminish
O	245	250	their
O	251	258	quality
O	259	261	of
O	262	266	life
O	267	270	and
O	271	281	negatively
O	282	288	affect
O	289	294	their
O	295	303	response
O	304	306	to
O	307	319	chemotherapy
O	319	320	.

O	321	332	Furthermore
O	332	333	,
O	334	340	inulin
O	341	356	supplementation
O	357	359	is
O	360	370	associated
O	371	375	with
O	376	379	the
O	380	389	reduction
O	390	392	of
O	393	407	cardiovascular
O	408	416	diseases
O	417	418	(
O	418	421	CVD
O	421	422	)
O	423	427	risk
O	427	428	.

O	429	431	To
O	432	441	determine
O	442	449	whether
O	450	456	inulin
O	457	472	supplementation
O	473	481	prevents
O	482	485	the
O	486	495	elevation
O	496	498	of
O	499	504	blood
O	505	513	pressure
O	514	516	in
O	517	522	women
O	523	527	with
O	528	534	breast
O	535	541	cancer
O	542	552	undergoing
O	553	564	neoadjuvant
O	565	572	therapy
O	573	577	with
O	578	594	cyclophosphamide
O	595	598	and
O	599	610	doxorubicin
O	610	611	.

O	612	616	This
O	617	620	was
O	621	622	a
O	623	633	randomized
O	633	634	,
O	635	641	double
O	641	642	-
O	642	647	blind
O	648	655	placebo
O	656	666	controlled
O	667	672	trial
O	673	678	which
O	679	687	included
B-eligibility	688	693	women
I-eligibility	694	698	with
I-eligibility	699	704	early
I-eligibility	704	705	-
I-eligibility	705	710	stage
I-eligibility	711	717	breast
I-eligibility	718	724	cancer
I-eligibility	725	735	undergoing
I-eligibility	736	747	neoadjuvant
I-eligibility	748	755	therapy
O	756	757	(
O	757	758	n
O	758	759	=
B-total-participants	759	761	38
O	761	762	)
O	762	763	.

O	764	772	Patients
O	773	777	were
O	778	786	randomly
O	787	795	assigned
O	796	798	to
O	799	810	participate
O	811	813	in
O	814	817	two
O	818	827	different
O	828	834	groups
O	835	837	to
O	838	845	receive
O	846	852	either
O	853	855	15
O	856	857	g
O	858	860	of
O	861	867	inulin
O	868	870	or
O	871	873	15
O	874	875	g
O	876	878	of
B-control	879	886	placebo
I-control	887	888	(
I-control	888	900	maltodextrin
I-control	900	901	)
O	902	905	for
O	906	908	21
O	909	913	days
O	913	914	.

O	915	919	Body
O	920	931	composition
O	932	935	and
O	936	941	blood
O	942	950	pressure
O	951	955	were
O	956	965	evaluated
O	966	972	before
O	973	976	and
O	977	982	after
O	983	986	the
O	987	1002	supplementation
O	1003	1009	period
O	1009	1010	.

O	1011	1016	Women
O	1017	1019	in
O	1020	1023	the
O	1024	1030	inulin
O	1031	1036	group
O	1037	1043	showed
O	1044	1045	a
O	1046	1051	lower
B-outcome	1052	1060	systolic
I-outcome	1061	1066	blood
I-outcome	1067	1075	pressure
I-outcome	1076	1077	(
I-outcome	1077	1080	SBP
I-outcome	1080	1081	)
O	1082	1087	after
O	1088	1091	the
O	1092	1107	supplementation
O	1108	1109	(
O	1109	1110	-
O	1110	1111	4
O	1111	1112	.
O	1112	1114	21
O	1115	1119	mmHg
O	1119	1120	,
O	1121	1122	p
O	1122	1123	<
O	1123	1124	0
O	1124	1125	.
O	1125	1128	001
O	1128	1129	)
O	1129	1130	.

O	1131	1138	However
O	1138	1139	,
O	1140	1143	SBP
O	1144	1153	increased
O	1154	1156	in
O	1157	1160	the
O	1161	1168	placebo
O	1169	1181	supplemented
O	1182	1187	group
O	1187	1188	.

B-outcome	1189	1198	Diastolic
I-outcome	1199	1204	blood
I-outcome	1205	1213	pressure
I-outcome	1214	1215	(
I-outcome	1215	1218	DBP
I-outcome	1218	1219	)
O	1220	1236	nonsignificantly
O	1237	1246	decreased
O	1247	1249	in
O	1250	1253	the
O	1254	1260	inulin
O	1261	1266	group
O	1266	1267	.

O	1268	1274	Inulin
O	1275	1290	supplementation
O	1291	1295	also
O	1296	1305	increased
B-outcome	1306	1309	BMI
O	1310	1311	(
O	1311	1312	p
O	1312	1313	<
O	1313	1314	0
O	1314	1315	.
O	1315	1318	001
O	1318	1319	)
O	1320	1323	but
O	1324	1331	reduced
B-outcome	1332	1335	BFP
O	1336	1337	(
O	1337	1338	p
O	1338	1339	=
O	1339	1340	0
O	1340	1341	.
O	1341	1344	288
O	1344	1345	)
O	1345	1346	.

O	1347	1358	Furthermore
O	1358	1359	,
O	1360	1371	confounding
O	1372	1381	variables
O	1381	1382	,
O	1383	1387	such
O	1388	1390	as
O	1391	1394	BMI
O	1394	1395	,
O	1396	1404	baseline
O	1405	1412	fasting
O	1413	1420	glucose
O	1420	1421	,
O	1422	1425	age
O	1425	1426	,
O	1427	1436	menopause
O	1437	1443	status
O	1443	1444	,
O	1445	1453	vomiting
O	1453	1454	,
O	1455	1467	constipation
O	1467	1468	,
O	1469	1472	and
O	1473	1480	chronic
O	1481	1491	medication
O	1492	1495	did
O	1496	1499	not
O	1500	1504	have
O	1505	1506	a
O	1507	1518	statistical
O	1519	1528	influence
O	1529	1533	over
O	1534	1537	the
O	1538	1544	inulin
O	1545	1551	effect
O	1552	1554	on
O	1555	1558	SBP
O	1558	1559	.

O	1560	1566	Inulin
O	1567	1582	supplementation
O	1583	1590	reduces
O	1591	1594	SBP
O	1595	1598	and
O	1599	1607	prevents
O	1608	1617	increases
O	1618	1620	in
O	1621	1624	DBP
O	1625	1627	in
O	1628	1633	women
O	1634	1638	with
O	1639	1645	breast
O	1646	1652	cancer
O	1652	1653	.

O	1654	1658	This
O	1659	1664	could
O	1665	1667	be
O	1668	1670	an
O	1671	1681	innovative
O	1682	1695	nutraceutical
O	1696	1704	approach
O	1705	1707	to
O	1708	1715	prevent
O	1716	1728	hypertension
O	1729	1736	present
O	1737	1739	in
O	1740	1745	women
O	1746	1750	with
O	1751	1755	this
O	1756	1760	type
O	1761	1763	of
O	1764	1770	cancer
O	1771	1773	at
O	1774	1776	an
O	1777	1782	early
O	1783	1788	stage
O	1789	1792	and
O	1793	1796	may
O	1797	1804	improve
O	1805	1808	the
O	1809	1816	quality
O	1817	1819	of
O	1820	1824	life
O	1825	1827	of
O	1828	1831	the
O	1832	1840	patients
O	1841	1844	and
O	1845	1850	their
O	1851	1861	prognostic
O	1862	1873	development
O	1874	1881	through
O	1882	1894	chemotherapy
O	1894	1895	.

O	1896	1900	This
O	1901	1906	trial
O	1907	1909	is
O	1910	1920	registered
O	1921	1925	with
O	1926	1945	ACTRN12616001532493
O	1945	1946	.
